Beyond Air® is an emerging medical device and biopharmaceutical company with groundbreaking technology. Through the LungFit® technology, we’ve developed the first and only systems with patented Ionizer technology that generate and deliver inhaled nitric oxide (iNO) on-demand using room air. Our technology helps eliminate potential challenges associated with traditional cylinder-based systems: - No handling and storing 45lb pressurized iNO cylinders with - All necessary components and accessories small enough to be stored at point-of-use - No pressure testing, manual purging, or potential NO2 exposure associated with these tasks Currently, the U.S. FDA is actively reviewing the premarket approval (PMA) submission for LungFit® PH System to treat persistent pulmonary hypertension of the newborn (PPHN). Beyond Air remains on track for LungFit PH commercial launch in the fourth quarter of 2021. LungFit Technology: visit https://www.beyondair.net/technology. Our investment in advancing the LungFit technology goes beyond the treatment of PPHN to include the treatment of severe lung infections. Our pipeline includes clinical trials for Community-Acquired Viral Pneumonia (including COVID-19) and Bronchiolitis, using higher nitric oxide concentrations through the LungFit PRO®. We are also conducting clinical trials for the at-home treatment of nontuberculous mycobacteria with the LungFit GO®. Pipeline, visit https://www.beyondair.net/pipeline. †Caution - LungFit® is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use. Reference: 1. Rimkus, M., Bathe, D., Montgomery, F. On-Demand Nitric Oxide for Ventilator-Based Nitric Oxide Inhalation: A Risk-Reduction Perspective. Abstracts of International Society for Aerosols in Medicine e.V. 22nd ISAM Congress, May 24, 2019. ©2021 Beyond Air Inc. All Rights Reserved.